Open access
Oct 2026
Profile and Predictors of Hepatitis B Surface Antigen Seroreversion Following PEG-IFNα with or Without Therapeutic Vaccine BRII-179 or siRNA Elebsiran: A Post Hoc Pooled Analysis of Two Randomized Controlled Trials in Patients with Chronic Hepatitis B Virus Infection
Background/Objectives: The clinical implications of HBsAg seroreversion following HBV functional cure therapies remain unclear. In two randomized phase 2 trials, therapeutic vaccine BRII-179 or siRNA elebsiran in combination with PEG-IFNα was evaluated versus PEG-IFNα monotherapy. This pooled analysis characterized the...
Zhi-Liang Gao, Bing-Liang Lin, G. Wong et al.
· Vaccines · 0 citations